Скачать или смотреть IO-IO and IO-TKI treatments could improve 5-year survival rate for aRCC

Anand Sharma, MD, D.Phil, MRCP, MBBS, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK, makes the case for immunotherapy as an effective backbone in advanced renal cell cancer (aRCC) treatment. A larger trial (NCT02231749) is highlighted to show a 43% 5-year survival rate with combined ipilimumab and nivolumab treatment. Dr Sharma is also hopeful new immunotherapy combinations (IO-IO) and immunotherapy plus tyrosine kinase inhibitor (IO-TKI) treatments will compliment immunotherapy well and improve this survival rate further. This interview took place at the American Clinical Society of Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.